Detalle Publicación

ARTÍCULO
A randomized phase II non-comparative study of PF-04691502 and gedatolisib (PF-05212384) in patients with recurrent endometrial cancer
Autores: Maria del Campo, Josep; Birrer, Michael; Davis, Craig; Fujiwara, Keiichi; Gollerkeri, Ashwin; Gore, Martin; Houk, Brett; Lau, Susie; Poveda, Andres; González Martín, Antonio; Muller, Carolyn; Muro, Kei; Pierce, Kristen; Suzuki, Mie; Vermette, Jennifer; Oza, Amit
Título de la revista: GYNECOLOGIC ONCOLOGY
ISSN: 1095-6859
Volumen: 142
Número: 1
Páginas: 62-69
Fecha de publicación: 2016
Resumen:
Gedatolisib administered by weekly intravenous infusion demonstrated acceptable tolerability and moderate activity in patients with recurrent endometrial cancer. PF-04691502 daily oral dosing was not well tolerated. Clinical benefit response criteria for proceeding to stage 2 were only met in the gedatolisib/stathmin-low arm. Stathmin-high expression did not correlate with greater treatment efficacy. ClinicalTrials.gov registration ID: NCT01420081